Trial
NCT05839626
A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sanofi
Collaborators
—
Condition
Relapsed/Refractory Multiple Myeloma
Intervention
SAR445514
Why stopped
Early discontinuation based on sponsor decision not driven by any safety concerns; phase 2 was not initiated.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-27